Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients

Abstract

Introduction: Anagliptin (ANA) improves dyslipidemia in addition to blood glucose levels. However, there are no comparative studies on the effects of ANA and other dipeptidyl peptidase-4 inhibitors on serum lipid profile. We compared the effects of ANA on serum lipid profile with those of alogliptin (ALO) in type 2 diabetes mellitus outpatients.

Materials and methods: The study participants were 87 type 2 diabetes mellitus patients who had been treated with dipeptidyl peptidase-4 inhibitors for ≥8 weeks and had a low-density lipoprotein cholesterol (LDL-C) level of ≥120 mg/dL. Participants were switched to either 200 mg/day ANA or 25 mg/day ALO for 24 weeks.

Results: There was no significant difference in percentage change in LDL-C level at 24 weeks between the ANA and ALO groups. Treatment with ANA for 12 weeks significantly decreased LDL-C levels, one of the secondary end-points. Treatment with ANA for 24 weeks significantly improved apolipoprotein B-100 levels, and the percentage change in LDL-C levels at 24 weeks correlated significantly with the percentage change in apolipoprotein B-100 levels in the ANA group.

Conclusions: The LDL-C-lowering effects of ANA and ALO at 24 weeks were almost similar in patients with type 2 diabetes mellitus. However, the results showed a tendency for a decrease in LDL-C level at 24 weeks in the ANA group, and that such improvement was mediated, at least in part, through the suppression of apolipoprotein B-100 synthesis.

Keywords: Apolipoprotein B-100; Dipeptidyl peptidase 4 inhibitor; Type 2 diabetes mellitus.

Figure 1

Serial changes in low‐density lipoprotein cholesterol (LDL‐C). (a, d) The anagliptin (ANA) group and (b, e) the alogliptin (ALO) group. (d, e) Data of patients with LDL‐C ≥ 140 mg/dL at baseline. (c) Data of all patients and (f) data of patients with LDL‐C ≥ 140 mg/dL at baseline. *P < 0.05, vs baseline, by anova.